| 查看: 256 | 回复: 1 | ||
| 当前主题已经存档。 | ||
abcd888898银虫 (正式写手)
|
[交流]
【转帖】Novo Nordisk receives approval for Victoza® in Japan
|
|
|
Novo Nordisk receives approval for Victoza® in Japan (20 January 2010) Read in PDF format Novo Nordisk receives approval for Victoza® in Japan Novo Nordisk today announced that the Japanese Ministry of Health, Labour and Welfare has approved Victoza® for the treatment of type 2 diabetes. Victoza® is the brand name for liraglutide, the first Glucagon-Like Peptide-1 (GLP-1) analogue approved in Japan, developed for the treatment of type 2 diabetes. Victoza® is indicated as monotherapy or as an add-on to sulphonylurea (SU) in people with type 2 diabetes. "The Japanese approval of Victoza® represents a major advancement in the treatment of type 2 diabetes and an important milestone for Novo Nordisk." says Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "We are excited to pioneer the GLP-1 market in Japan, where we are convinced Victoza® will prove to be a valuable treatment option for people with type 2 diabetes. The clinical studies conducted in Japan showed Victoza® to provide superior glucose control with a low risk of hypoglycaemia." Novo Nordisk expects to launch Victoza® in Japan in the first half of 2010 upon completion of price negotiations. |
回复此楼
2楼2010-01-20 20:07:57